Market Pulse
Sports Direct results sees employees miss out
High street retailer Sports Direct reported on a “disappointing” year on Thursday, with retail revenue excluding Heatons improving by just 0. 6%.
London pre-open: FTSE 100 called higher on oil bounce and Fed reticence
London's larger shares are expected to start on the front foot thanks to a positive Wall Street session and an oil rebound, while mid-caps are predicted to have a tougher time as the Brexit worries continue to impinge.
UK business confidence drops but still above crisis lows, Lloyds finds
UK business confidence and economic optimism fell to a four-year low in the week after the Brexit referendum but still well off the lows of 2008, according to a survey by Lloyds Bank that mirrored recent findings on consumer confidence.
Whitbread enters sale-and-leaseback with Legal & General
Hospitality group Whitbread announced on Thursday that it has exchanged agreements with Legal & General for the sale-and-leaseback of its 389-room ‘Hub by Premier Inn’ hotel in Kings Cross, due to open in 2017, in exchange for a 25 year lease agreement.
Thursday newspaper round-up: China deal, pension deficits, BT, Amazon
Chinese officials are open to launching trade negotiations with Britain in the aftermath of the Brexit vote, raising hopes that the UK’s economy can receive a boost after it leaves the EU. Critics of Brexit warned that the UK could find itself alone and cut off from the world economy outside the EU, but the indications from China are that deals are possible. - Telegraph.
Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)
Novartis International AG / Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
Novartis International AG / Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment.
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Novartis International AG / Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
Novartis International AG / New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
Novartis International AG / Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.